Sarah Alexandrou

St Vincent's Clinical School, UNSW Sydney
Sydney, NSW 2010, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans.

BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans.

Journal: Molecular cancer

Published: July 08, 2025

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: April 15, 2025

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 17, 2024

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

Journal: Nature communications

Published: July 11, 2023

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.

Journal: Nature structural & molecular biology

Published: December 13, 2022

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 01, 2021

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Journal: Nature medicine

Published: August 20, 2020

Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer.

Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer.

Journal: Cancers

Published: July 05, 2020

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.

Journal: NPJ breast cancer

Published: February 22, 2020

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Journal: Endocrine-related cancer

Published: February 11, 2020

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.

Journal: Breast cancer research : BCR

Published: February 05, 2020

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

Journal: International journal of molecular sciences

Published: December 16, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026